Clinical trialNCT04817761TerminatedPhase 2/PHASE3Interventional

SPARK-ALL: Calaspargase Pegol in Adults With ALL

SponsorInstitut de Recherches Internationales ServierEnrollment42Acute Lymphoblastic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honorhealth Cancer Transplant Institute
Scottsdale, Arizona, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Univeristy of California
Los Angeles, California, United States
University of California Irvine Health (uci Health)
Orange, California, United States
University of Miami Health System - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Chicago Medicine
Chicago, Illinois, United States
University of Kansas Cancer Center - Richard and Annette Bloch Cancer Care Pavilion
Westwood, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Weymouth, Massachusetts, United States
Northwell Health Cancer Institute
Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Nyu Langone/laura and Isaac Perlmutter Cancer Center
New York, New York, United States
Duke University
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oregon Health & Science University (ohsu)
Portland, Oregon, United States
Jefferson Health
Philadelphia, Pennsylvania, United States
Baptist Clinical Research Institute
Memphis, Tennessee, United States
Intermountain Healthcare (ihc)
Salt Lake City, Utah, United States
University of Washington/seattle Cancer Care Alliance/fred Hutch
Seattle, Washington, United States
West Virginia University Cancer Institute
Morgantown, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Calaspargase pegol →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Jul 2021
Primary completion: 21 Mar 2025
Completion: 21 Mar 2025
Last update posted: 18 Feb 2026
Registered enrollment: 42
Registry id: NCT04817761

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.